Thursday, November 30, 2017
The programme created to promote start-ups specialising in innovative solutions for patients will hold its pitch day today
Today, seven entrepreneurs selected as finalists will defend their projects before a panel of top industry experts
The winning projects will be given mentoring, coaching, co-working spaces and financial support according to the project
Madrid, 28 November 2017- Revolutionising health and facilitating and improving people's lives is one of the main goals of #ChemoStart: the programme that Insud Pharma (formerly Chemo Group) created at the start of the year to promote innovative health projects.
Today, the programme is taking a step forward and holding its PITCH DAY. Since its launch, #ChemoStart has received more than twenty projects of very high quality, specialising in innovative solutions for patients both in e-health, as well as predictive analytics, biosensors and genomic medicine, among others. And today, the seven entrepreneurs selected as finalists will present their business proposals to a panel of top industry experts.
The panel comprises: Dr Hugo Sigman, Argentinian businessman and founder of Chemo Group; Mariano Sigman, founder of the Integrative Neuroscience Laboratory at the University of Buenos Aires; Jorge Alemany, Manager of the Madrid office of Spherium Biomed; Agustín Maciá, founder of Nuubo; Michael Tadros, Senior Manager Botín Foundation; Sylvain Sachot, Investment Manager at Ysios and Leandro Sigman, Chairman of Insud Pharma and main driver of the initiative.
Insud Pharma will offer the winning projects and entrepreneurs mentoring and coaching from experts to promote their projects, co-working spaces in which to develop their projects, as well as financial support and investment, according to the characteristics and needs of each project.
Insud Pharma is a pharmaceutical multinational with a history spanning back over four decades and a commitment to preserve and improve the health and well-being of people. The Group is present in over 40 countries in Europe, America, Asia and Africa and has more than 6,000 professionals, fifteen plants, 10 R&D centres and more than 35 affiliated pharmaceutical companies, which provide high-quality and affordable drugs and services to patients across the world